Premarin Side Effects Lawsuit

Premarin Side Effects Lawsuit

Premarin Side Effects Lawsuit

On August 4, 2011, the Supreme Court of British Columbia allowed a class action lawsuit against Pfizer’s subsidiary Wyeth Pharmaceuticals, the maker of hormone drug Premarin, to proceed. The lawsuit originally filed by Dianne Stanway, a Sechelt native, represents all women who developed breast cancer due to the use of the drug between 1977 and 2003 to ease symptoms of menopause. The plaintiffs have accused Wyeth Canada of marketing the drug without proper safety research and warning for patients.

Premarin, a mixture of estrogen hormones, has been marketed by Wyeth since 1942 as a hormone replacement therapy for the treatment of menopause symptoms, such as vaginal dryness, itching, irritation, burning, and hot flashes. Its primary goal is to boost production of sex hormone estrogen in women with ovarian failure or those lacking natural estrogen in their body. The drug therapy is also prescribed to prevent osteoporosis in postmenopausal women and used in the cancer treatment in both men and women.

Premarin Side Effect Complaints

Premarin has been linked to heart problems, breast cancers, blood clot, vaginal bleeding, liver disease and birth defects. The first comprehensive research report on the drug was made public in December 1975. The study, conducted by Ralph Nader’s Health Reserach Group, discovered that taking the drug on long-term basis put patients at the risk of uterine cancer. The findings were presented to the Advisory Committee of Gynaecology and Obstetrics constituted by the FDA.

In 1976, the FDA directed the manufacturer to attach a label warning to the drug informing users about

Read more: Premarin Side Effects Lawsuit

Metronidazole Recall Lawsuit

Metronidazole Recall Lawsuit

Teva Pharmaceuticals U.S.A. has recalled their antibiotic used in treating anaerobic bacteria and parasites.

The drug Metronidazole Tablets USP, 250 mg has been recalled nationwide due to underweight tablets which may not have enough of the active ingredient to fight infections such as those the drug is intended to treat including some sexually transmitted diseases, acute intestinal amebic dysentery, amebic liver abscess, gynecologic infections, bone and joint infections, and lower-respiratory infections, among others.

Read more: Metronidazole Recall Lawsuit

Nuvaring Side Effects Lawsuit

Nuvaring Side Effects Lawsuit

NuvaRing, a composition of ethinyl estradiol and etonogestrel, is a contraceptive vaginal ring available on prescription. The flexible plastic contraceptive ring, manufactured by Merck & Co, Organon BioSciences, and Schering-Plough, releases a low dose of progestin and estrogen hormones over a period of three weeks. The FDA approved NuvaRing on October 3, 2001, and over 1.5 million women worldwide use the contraceptive ring. However, two studies link NuvaRing with serious device-related side effects. More than 15.1 percent of the users have discontinued the use of the device after experiencing sexual problems, foreign object sensation, and expulsion.

NuvaRing Lawsuit

More than 730 personal injury and wrongful death Lawsuit have been filed against the manufacturer and marketer of NuvaRing for failing to warn consumers about the health risks associated with NuvaRing, including possible blood clot complications and related injuries, such as deep vein thrombosis, pulmonary embolism, heart attacks and strokes.

In March 2008, a lawsuit was filed against Merck for not disclosing health risks associated with the device usage. The lawsuit claims that the use of NuvaRing had caused death of the plaintiff's wife. While Merck continues to deny the allegations, trials for many Lawsuit are scheduled for 2012. Many Lawsuit find major problems with the advertising of NuvaRing, which downplays the threat of risks associated with the device.

Read more: Nuvaring Side Effects Lawsuit

Bayer Side Effects

Bayer Side Effects

Bayer FDA Warning Letter

              A warning was issued to Bayer AG’s Bergkamen, Germany facility following an inspection in March resulted in concern among the FDA regarding the pharmaceutical giant’s ability to efficiently test and monitor quality. In the warning letter, dated August 5, 2009, the FDA speaks on the testing processes for the pharmaceuticals and the quality of the ingredients used to make the drugs.

When Bayer responded by indicating they were addressing the issues, the FDA acknowledged the action taken but said the steps did not sufficiently address some of the issues. Inspectors said that Bayer did not measure the drug ingredient quality on individual test results, but rather by utilizing an average of a couple samples. Eight batches of the pharmaceutical, which used the non-acceptable averaging method, were shipped to the United States. The Yaz ingredient, drospirenone, was found which noted that these drugs are marketed by Bayer but also means that the environment that the drugs were made in was mixed.  

Read more: Bayer Side Effects